Skip to main content

Table 1 Characteristics of the study population

From: Impairment of endothelial function in Parkinson’s disease

 

Parkinsonʼs disease

Controls

p-value

Number of subjects

41

41

 

Male/female sex

24/17 (58.5%/41.5%)

24/17 (58.5%/41.5%)

1.0

Age (years)

65.4 ± 9.1

65.3 ± 10.7

0.947

BMI (kg/m2)

27.5 ± 4.8

27.5 ± 3.6

0.996

Arterial hypertension

20 (48.8%)

21 (51.2%)

0.825

Coronary heart disease

6 (14.6%)

6 (14.6%)

1.0

Diabetes mellitus

8 (19.5%)

7 (17.1%)

0.775

Dyslipidaemia

6 (14.6%)

8 (19.5%)

0.557

Smoking

6 (14.6%)

6 (14.6%)

1.0

RHI

1.8 ± 0.5

1.9 ± 0.5

0.478

Endothelial dysfunction

19 (46.3%)

14 (34.1%)

0.260

Hoehn and Yahr score

0, 2.5 (0–4.0)

Duration of PD since diagnosis (years)

0, 5.0 (0–15.0)

LED (mg)

900.0 (0–2280.0)

L-dopa

31 (75.6)

Dopamine agonists

25 (61%)

COMT inhibitors

18 (43.9)

MAO-B inhibitors

14 (34.1)

Amantadine

6 (14.6%)

  1. PD Parkinsonʼs disease, BMI body mass index, RHI reperfusion hyperemia index, PB blood pressure, LED levodopa equivalent dose, COMT catechol-O-methyl transferase, MAO-B monoamine oxidase